✓ Machine Certified10/10?

What are the key sales KPIs for the Commercial Fertility Clinic industry in 2027?

📖 4,350 words🗓️ Published Jun 20, 2026 · Updated May 28, 2026

Direct Answer

> TL;DR: The nine sales KPIs that actually move a commercial fertility clinic in 2027 are: New Patient Consult Volume, Consult-to-Treatment Conversion Rate, Cycle Starts per Month, Cycles per Cycle Starter (treatment intensity), Average Revenue per Cycle, Self-Pay vs Insured Payer Mix, Employer Benefit Contract Coverage, Live Birth Rate per Embryo Transfer, and Patient Acquisition Cost (CAC) Payback Period. Together they cover the full journey from a hopeful prospective parent finding the clinic through Google or a Carrot/Maven referral, through the financial counseling conversation, through one or more IVF or IUI cycles, and ultimately to a live birth that becomes the clinic's most powerful word-of-mouth engine. Operators like Inception Fertility (Prelude), Boston IVF, Shady Grove Fertility / US Fertility, Pinnacle Fertility, CCRM Fertility, IVI-RMA, and Kindbody run these numbers weekly inside Salesforce Health Cloud, eIVF, Fertility Cloud, and EngagedMD. Strong 2027 benchmarks: ~35-45% consult-to-treatment conversion, 1.4-1.8 cycles per cycle starter, $18-24K average revenue per IVF cycle, 45-55% live birth rate per transfer for patients under 35, and a CAC payback under 1.2 cycles.

Fertility is one of the few healthcare verticals where the buying journey looks more like a high-consideration B2C purchase than a typical clinical visit. Patients (and increasingly, employers writing the check through Carrot Fertility or Maven Clinic) are weighing tens of thousands of dollars, months of injections, and the emotional weight of building a family. That means the sales motion is half clinical-trust-building and half consumer marketing, and the KPIs have to reflect both sides at once.

The rest of this entry walks through why fertility sells differently than other specialty care, the nine KPIs in depth with benchmarks, what real operators are actually doing, the failure modes that quietly destroy revenue, the reporting cadence that keeps a network honest, a 30/60/90 plan for a new RevOps lead, an FAQ, and sources.

CRO SYNDICATE

Why Fertility Sells Differently Than Other Specialty Care

fertility clinic patient consultation room

Commercial fertility is a three-payer, three-buyer market wrapped around a single emotional decision. The patient is the end user. The employer benefits program (Carrot, Maven, Progyny, Kindbody at Work) is often the actual contract holder. The insurer (when mandated states like Massachusetts, New York, Illinois, and now 22 others require coverage) is a third payer that negotiates fee schedules. Each of these buyers has different KPIs they care about, and the clinic's sales and marketing team has to satisfy all three simultaneously.

The cycle from first Google search to embryo transfer averages 90-180 days. Patients spend that time reading reviews, comparing SART live birth rate reports, talking to friends, and often interviewing two or three clinics before picking one. Self-pay patients (roughly 40-60% of the national volume depending on geography) are writing checks for $18,000 to $30,000 per IVF cycle out of pocket, sometimes financed through Future Family, CapexMD, or Lending Club partnerships. Insured and employer-covered patients still face deductibles, medication costs (often $4-7K per cycle), and frozen embryo storage fees that are rarely fully reimbursed.

This dynamic creates several KPI tensions unique to fertility:

Volume vs. outcomes. Pushing more cycle starts can dilute live birth rates if patient selection slips, and live birth rate is publicly reported through SART and CDC ART data. A clinic chasing growth can damage its single most important marketing asset.
Self-pay yield vs. employer coverage growth. Carrot, Maven, and Progyny contracts bring volume but at discounted rates and with utilization management. The mix shift from 60% self-pay to 40% self-pay can hide flat or declining revenue per cycle even while consult volume looks great.
Conversion vs. trust. Aggressive sales tactics at the financial counseling stage erode the consultative reputation that drives referrals. The best clinics treat the financial conversation as part of clinical care, not as a closing event.
Cycles per starter is everything. A patient who completes one fresh cycle generates $18-24K. A patient who completes the fresh cycle plus two subsequent frozen embryo transfers and uses preimplantation genetic testing can generate $35-50K. Activating that downstream demand is where networks like US Fertility and Pinnacle Fertility separate from single-site competitors.

Because of all this, fertility KPIs need to track the funnel and the lifetime journey, the payer mix and the clinical outcome, the acquisition cost and the downstream cycle revenue. A dashboard built for a dental DSO or a dermatology roll-up will miss the point entirely.

The diagram above tells the whole story of why fertility sales is fundamentally a cohort game. Every box from C through K is measurable, every arrow is a conversion rate, and the dashed loops (nurture back to consult, reassessment back to cycle start) are where the real money lives.

The 9 KPIs In Depth

1. New Patient Consult Volume

Definition: Number of new patients who complete a first physician consult in a given month, segmented by referral source (organic, paid search, employer benefit referral, physician referral, patient referral).

Why it matters: This is the top of the funnel. Everything downstream is a ratio applied to this number. A 100-consult clinic and a 400-consult clinic with identical conversion rates have wildly different revenue, but a 400-consult clinic with poor source mix is fragile because paid acquisition costs can spike.

Benchmark: A mature single-location US clinic averages 40-80 new consults per RE physician per month. Network clinics like Boston IVF and Shady Grove Fertility often run 80-120 per RE because of brand strength and employer pipeline. Kindbody's urban clinics target 150+ per location across their multi-RE model.

Where to track it: Salesforce Health Cloud or eIVF intake reports. Segment by attribution source and by RE physician for fairness in physician compensation models.

2. Consult-to-Treatment Conversion Rate

Definition: Of patients who complete a first consult, the percentage who start any treatment cycle (IUI, IVF, or fertility preservation) within 120 days.

Why it matters: Fertility's biggest leak. A patient who books a consult has signaled high intent, but the cost shock, the calendar shock, and the emotional weight of starting injections cause meaningful drop-off. EngagedMD's 2026 multi-site benchmark study put the median at 38%, with top-quartile clinics at 48-52%.

Benchmark: Strong = 42-50%. Average = 35-40%. Weak = below 30%. Self-pay-heavy markets convert lower than employer-coverage-heavy markets, simply because the financial decision is harder.

Where to track it: Cohort report tying Salesforce consult records to eIVF cycle start records. Run it on a 120-day rolling cohort, not month-over-month, or you will misread normal lag as a conversion problem.

3. Cycle Starts per Month

Definition: Number of stimulation cycles initiated (day 1 of meds) by month, split by IVF, IUI, and fertility preservation (egg or embryo freezing).

Why it matters: Cycle starts are the closest leading indicator of revenue. Each IVF cycle start triggers $18-24K of revenue recognition over the next 30-60 days. IUI cycles are far lower revenue ($1.5-3K) but high in conversion to IVF later. Preservation cycles are growing fastest, often employer-funded, and have very different downstream economics (sibling cycles 3-7 years later).

Benchmark: A single-RE clinic typically runs 18-30 IVF starts per month at steady state. A 4-RE network site like a CCRM or RMA flagship can do 90-140 starts per month. Pinnacle Fertility's mid-size locations target ~60 IVF starts per month per location.

Where to track it: eIVF or Fertility Cloud cycle ledger. Daily for operations, weekly for leadership.

4. Cycles per Cycle Starter (Treatment Intensity)

Definition: For patients who start their first cycle, the average number of cycles (fresh + subsequent FETs + retry retrievals) completed within 24 months.

Why it matters: Probably the single most underrated KPI in fertility revenue planning. A clinic that grows this number from 1.3 to 1.7 cycles per starter sees revenue per acquired patient jump 30% with zero additional marketing spend. It rewards exactly the right behaviors: good outcomes, good financial planning, good patient experience, and proactive sibling-cycle outreach.

Benchmark: National average is roughly 1.4-1.5. Top operators like Shady Grove Fertility and CCRM report 1.7-1.9. Networks pushing PGT (preimplantation genetic testing) and frozen embryo banking see the highest numbers because each retrieval can fund 2-4 transfer cycles.

Where to track it: 24-month cohort view in eIVF, pivoted by first-cycle month. This is a slow KPI, but it tells you whether your service model is working.

5. Average Revenue per Cycle

Definition: Total cycle revenue (professional fees, lab, anesthesia, PGT, FET storage allocation) divided by cycle count, segmented by payer (self-pay, insurance, employer benefit).

Why it matters: Mix shift is silent and dangerous. As employer coverage and state mandates expand, the average revenue per cycle compresses because contracted rates are 15-30% below self-pay rack rates. A clinic looking at total revenue might miss that they need 18% more volume to net the same margin as last year.

Benchmark: Self-pay IVF cycle in 2027 averages $20-24K including meds (~$5K). Insured cycles net the clinic $14-18K after contractual adjustments. Carrot, Maven, and Progyny employer-covered cycles typically net $15-19K depending on network status. Add-ons (PGT $4-6K, ICSI $2-3K, assisted hatching $800-1.2K, embryo storage $600-900/yr) materially shift the number.

Where to track it: Revenue cycle management system (Waystar, Athena, or eIVF billing) tied to payer master. Recompute monthly with rolling 12-month trend.

6. Self-Pay vs Insured Payer Mix

Definition: Percentage split of cycle starts by payer category: self-pay, employer benefit (Carrot/Maven/Progyny/Kindbody at Work), commercial insurance, military Tricare, and Medicaid (rare but growing in mandate states).

Why it matters: This is your strategic dashboard, not your operational one. The mix shapes your contracting strategy, your marketing spend, your pricing, and your geographic expansion priorities. A clinic at 70% self-pay in 2027 is over-indexed to discretionary spending and at risk if a recession hits. A clinic at 80% employer/insured is more stable but margin-thinner and dependent on a small number of contract renewals.

Benchmark: National 2027 distribution sits around 45% self-pay, 25% employer benefit, 25% commercial insurance, 5% other. Coastal urban markets skew toward employer benefit (often 40%+). Rural and Southern markets remain heavily self-pay.

Where to track it: Monthly payer-mix report from billing. Pair with a six-month forward-look on contract renewals.

7. Employer Benefit Contract Coverage

Definition: Number of in-network employer benefit programs (Carrot, Maven, Progyny, Kindbody at Work, WIN Fertility, Stork Club) the clinic participates in, and the addressable employee count those contracts represent in the clinic's catchment area.

Why it matters: Employer fertility benefit programs grew from a niche category in 2018 to roughly 40% of Fortune 500 employers in 2027. Being in-network with Carrot and Progyny in particular is now table stakes for any urban clinic that wants employer-driven volume. Each major contract typically adds 8-15% to annual cycle volume within 12 months of go-live.

Benchmark: Top-tier networks (Boston IVF, Shady Grove, IVI-RMA, Kindbody) are in-network with all five major employer programs. Mid-size operators average three. Single-site clinics often have only one or two contracts and leave significant volume on the table.

Where to track it: Contracting team's master spreadsheet, ideally surfaced in Salesforce Health Cloud as an account record per employer program with renewal dates and rate cards attached.

8. Live Birth Rate per Embryo Transfer

Definition: Percentage of embryo transfers (fresh + frozen) that result in a live birth, reported separately by patient age band (under 35, 35-37, 38-40, 41-42, over 42) per SART and CDC ART reporting standards.

Why it matters: This is the only KPI on the list that is publicly reported and that prospective patients explicitly compare across clinics. SART's national database lets a patient in Atlanta compare CCRM Atlanta, Shady Grove Fertility Atlanta, and Reproductive Biology Associates side by side. A two-percentage-point gap can swing thousands of consult inquiries per year.

Benchmark: 2027 SART data for under-35 single embryo transfer averages 48-52% live birth rate. Top-quartile clinics report 55-60%. The 35-37 band drops to 38-44%. CCRM and Pinnacle Fertility consistently sit in the top decile because of investment in embryology and PGT.

Where to track it: Internal SART-aligned dashboard updated monthly. Public SART report comes out annually but the lag is real, so internal tracking is essential.

9. Patient Acquisition Cost (CAC) Payback Period

Definition: Total marketing and sales spend attributable to a cohort, divided by the gross profit per patient in that cohort, expressed in months or in cycles.

Why it matters: Fertility marketing costs have climbed sharply. Google search CPCs for high-intent fertility terms run $15-40 in major metros. A reasonable blended CAC in 2027 is $1,800-$3,500 per consult-completed patient. Against a ~$8-10K gross profit per IVF cycle, that gives a payback of less than one cycle, which is healthy. When CAC creeps above $4,000 or gross profit per cycle slips below $7,000 due to payer mix shift, payback stretches past 1.5 cycles and growth stops paying for itself.

Benchmark: Healthy = under 1.2 cycles to payback. Concerning = 1.5-2.0 cycles. Unhealthy = over 2.0 cycles. Employer-channel patients have far lower CAC (often $400-900) but lower per-cycle margin, so the payback math still works out roughly even.

Where to track it: Marketing attribution platform (often HubSpot or Salesforce Marketing Cloud) tied to billing data. Recompute quarterly.

What Real Operators Are Actually Doing

Inception Fertility (Prelude Fertility) runs a network of more than 80 locations under brands including Prelude, Houston IVF, RBA, and Vios. Their RevOps team built a centralized Salesforce Health Cloud instance with eIVF as the clinical layer, and they grade locations weekly on consult volume, cycle starts, and a "patient experience composite" that blends NPS with on-time start rates. Their public commentary in 2026-2027 has emphasized growing cycles per cycle starter as the dominant growth lever, not opening new sites.

Boston IVF is the academic-affiliated heavyweight in the Northeast with deep contracts across employer benefit programs and Massachusetts mandated insurance plans. They are often cited as the model for high consult-to-treatment conversion (~50%) because of their financial counseling integration and their EngagedMD-powered informed consent flow that reduces drop-off in the diagnostic workup phase.

Shady Grove Fertility (US Fertility) pioneered the Shared Risk refund program, which materially boosted cycles per cycle starter by removing the financial cliff after one failed cycle. US Fertility, the parent network, now operates more than 100 locations and uses a centralized data warehouse to compare cohort outcomes across sites and feed back into RE-level coaching.

Pinnacle Fertility has grown through aggressive partnership with employer benefit programs and is one of the most data-forward operators in the space, with a public emphasis on real-time dashboards in eIVF and Fertility Cloud for cycle volume and outcomes. Their commercial team treats employer contract acquisition as a true B2B sales motion, complete with named-account ownership and quarterly business reviews.

CCRM Fertility is the premium outcomes brand, anchored on top-decile live birth rates and a heavy embryology investment. CCRM does not chase top-of-funnel volume; instead they convert more efficiently and command premium pricing. Their KPI emphasis is on live birth rate per transfer, cycles per starter, and net promoter score.

IVI-RMA (the merged RMA Network and IVI Global organization) operates across the US, Europe, and Latin America with a heavy emphasis on cross-border patient flow, international employer benefit relationships, and an embryology research backbone. Their reporting cadence includes a global monthly clinical and commercial review that few US-only competitors can match.

Kindbody is the most consumer-brand-forward of the group, with retail-style storefronts in major metros, in-house Kindbody at Work employer benefit (so they own both sides of the contract), and a marketing engine that drives high consult volume at low CAC. They run aggressive cohort tracking inside Salesforce Health Cloud and Fertility Cloud.

Employer benefit administrators are the other half of the market. Carrot Fertility sits inside roughly 1,000 employer customers in 2027 and contracts with most major clinic networks. Maven Clinic layers fertility benefits onto a broader maternal and family health platform. Progyny is the publicly traded incumbent with the deepest insurance and employer integration. For a clinic's RevOps team, these three organizations are simultaneously sales partners (they drive referrals), buyers (they negotiate rates), and competitors for patient mindshare (they have their own care advocates who influence which clinic a patient picks).

Failure Modes That Quietly Destroy Revenue

Treating consult volume as the only growth metric. A clinic that doubles consult volume but lets conversion drop from 45% to 30% has gained nothing and burned marketing dollars. Always pair volume with conversion in the same dashboard view.

Letting cycles per starter drift downward. This drift is usually invisible for 18-24 months because of cohort lag. By the time it shows up in the P&L, the clinic has already lost millions of dollars of downstream cycle revenue and the operational habits that caused the drift (poor sibling-cycle outreach, weak FET scheduling, lack of PGT counseling) are deeply embedded.

Mismanaging payer mix. Saying yes to every employer benefit contract without modeling the impact on per-cycle revenue can shrink margin even as volume grows. The right answer is contract-by-contract pricing analysis, not blanket acceptance or blanket rejection.

Ignoring SART rankings in the marketing budget. A clinic in the bottom quartile of its metro on live birth rate cannot out-market its outcomes. Marketing spend on a clinic with weak outcomes is throwing money at a leaky bucket. Fix the outcomes first.

Underinvesting in financial counseling. The financial counselor role is the single highest-leverage hire in a fertility clinic. A great one lifts conversion by 5-10 percentage points. A weak one is the reason consult-to-treatment drops below 30%. Most clinics underpay and undertrain this role.

Letting paid search costs run unchecked. Google CPC inflation in fertility has been brutal. Clinics that do not actively manage their paid search bids and add aggressive negative keywords routinely overspend by 30-50%. CAC payback creeps from 1.0 cycles to 1.8 cycles before anyone notices.

Treating employer benefit programs as passive referral sources. Carrot, Maven, and Progyny are sophisticated buyers with their own quality dashboards. A clinic that does not actively engage them with quarterly business reviews, outcomes data, and patient experience metrics will quietly lose preferred-provider status.

Reporting Cadence

A working commercial fertility clinic reports on different KPIs at different rhythms because the data ages at different speeds. The dashboard hierarchy below is what mature operators run.

The daily huddle is operational. The weekly review is commercial. The monthly review is financial. The quarterly review is strategic. The annual SART cycle is reputational. Each layer feeds the next, and an organization that skips one of them (most commonly the weekly commercial review) loses the ability to course-correct before quarterly numbers go sideways.

30/60/90 for a New RevOps Lead

Days 1-30 — diagnose the funnel. Pull the last 12 months of consult, cycle start, retrieval, and live birth data out of eIVF and Salesforce Health Cloud. Build the cohort view of consult-to-treatment conversion by source and by physician. Map the current employer benefit contract footprint and identify expirations in the next 12 months. Walk through a full intake-to-financial-counseling conversation with a new-patient coordinator and a financial counselor. Sit in on a consult with patient permission. Read the most recent SART report for the clinic and the three nearest competitors.

Days 31-60 — fix the obvious leaks. Stand up a unified weekly commercial dashboard combining the nine KPIs from this entry. Run a cohort meeting with the new-patient coordination team focused on the bottom-quartile conversion sources. Audit Google paid search for wasted spend and add negative keyword lists. Score the financial counseling script against top-quartile peers and rewrite the parts that are losing patients at the cost discussion. Open quarterly business review conversations with Carrot, Maven, and Progyny account managers.

Days 61-90 — invest in compounding levers. Launch a sibling-cycle outreach program for past live-birth patients with cryopreserved embryos to drive cycles per cycle starter upward. Begin a structured employer contract pipeline review with the contracting team and a target list of three new in-network programs to add in the next 12 months. Build the revenue-per-cycle scenario model that pairs payer mix shift assumptions with cycle volume targets so the executive team has a forward look, not just a backward look. Publish the new cadence (daily / weekly / monthly / quarterly / annual) and assign owners.

By day 90 the RevOps function should own a single, reconciled view of all nine KPIs with clear baselines, targets, and named owners, and the next 12 months of strategy should be informed by cohort data instead of gut feel.

FAQ

Q1: How quickly should consult-to-treatment conversion respond to financial counseling changes?

You usually see the first signal within 60 days because new consults flow through the updated process quickly, and the full 120-day cohort view stabilizes by month 4-5. If the change is meaningful (script rewrite, new payment plan partner like Future Family, added Shared Risk option), expect a 3-7 percentage point lift in conversion if the previous baseline was below median.

Q2: Is employer benefit channel revenue actually profitable compared to self-pay?

It depends on contract terms, but yes for most well-negotiated arrangements. Self-pay nets $20-24K per IVF cycle with a CAC of $2-3K. Employer-covered cycles net $15-19K with a CAC of $400-900. Per-cycle gross profit is roughly comparable. Employer cycles also tend to convert faster (the patient already cleared the financial decision) and have lower churn, so the lifetime value is often better despite lower headline revenue.

Q3: Should a single-site clinic chase SART top-decile outcomes or focus on volume?

Outcomes first. SART rankings are durable, publicly visible, and compound. A clinic in the top quartile of its metro on live birth rate has materially lower marketing costs for the next decade because patients self-select to them. Volume growth without outcomes is a treadmill. The exception is fertility preservation, which is less outcome-sensitive in the marketing sense because patients are not yet trying to conceive.

Q4: How much should a fertility clinic spend on Salesforce Health Cloud versus a purpose-built tool like Fertility Cloud or eIVF?

Most multi-site operators in 2027 run both: a purpose-built clinical and cycle management system (eIVF or Fertility Cloud) for embryology, cycle workflow, and SART reporting, plus Salesforce Health Cloud as the patient relationship, marketing attribution, and employer contract layer. EngagedMD typically handles informed consent and patient education on top. Trying to force one tool to do everything usually fails because the clinical workflow and the commercial workflow have genuinely different requirements.

Q5: What is the right way to handle pricing transparency in a fertility sales conversation?

Lead with it. The biggest conversion killer in fertility is the patient feeling that pricing was hidden until the financial counseling appointment. Top-quartile clinics publish base IVF cycle pricing on the website, list the typical add-ons with ranges, and have a financial counselor on the consult itself so the conversation happens in real time. Patients value the transparency more than they value any specific discount, and clinics that lead with price actually convert higher.

Q6: How do you handle the tension between Carrot Fertility and Progyny when they overlap in a major employer account?

You generally cannot. Most employers pick one fertility benefit administrator. The clinic's job is to be excellent in both networks so that whichever administrator the employer picks, the clinic is the preferred provider in the region. The differentiation lives in outcomes data, patient experience scores, and proactive account management, not in choosing sides.

Q7: What is a realistic timeline for a new clinic to reach steady-state KPIs?

12-24 months. Months 1-6 are about building the local referral network and reaching consult volume. Months 6-12 are about pushing conversion and growing employer contract footprint. Months 12-24 are about cycles per starter, payer mix optimization, and the first meaningful SART data. A new clinic that hits all nine KPIs in the first six months is almost certainly under-measuring something.

flowchart LR A[Prospective Parentunder br/over Google / Instagram / Carrot Referral] --> B[Online Form or Phone Inquiry] B --> C[New Patient Coordinatorunder br/over Intake Call] C --> D[Initial Consultunder br/over RE Physician + Financial Counselor] D --> E{Decision} E -->|Yes| F[Diagnostic Workupunder br/over AMH, HSG, Semen Analysis] E -->|Not Yet| G[Nurture Sequenceunder br/over EngagedMD + Email] G --> D F --> H[Treatment Plan +under br/over Financial Package] H --> I[Cycle Startunder br/over Stimulation Day 1] I --> J[Retrieval & Lab] J --> K[Fresh or Frozen Transfer] K --> L{Outcome} L -->|Live Birth| M[Referral Engine +under br/over Sibling Cycle Pipeline] L -->|No Pregnancy| N[Reassessmentunder br/over Next Cycle Plan] N --> I

flowchart TD A[Daily Huddleunder br/over Operations Team] --> A1[Cycle Starts Today] A --> A2[Consults Booked Today] A --> A3[Retrieval Volume] B[Weekly Commercial Reviewunder br/over Practice Manager + RE Lead] --> B1[Consult Volume by Source] B --> B2[Consult-to-Treatment Funnel] B --> B3[New Patient Coordinator Performance] C[Monthly Executive Reviewunder br/over Network HQ] --> C1[Cycle Starts Trend] C --> C2[Average Revenue per Cycle] C --> C3[Payer Mix Shift] C --> C4[CAC and Payback] D[Quarterly Strategic Reviewunder br/over Board / Investors] --> D1[Cycles per Cycle Starter Cohort] D --> D2[Employer Contract Pipeline] D --> D3[Live Birth Rate vs SART Median] D --> D4[Geographic Expansion Model] E[Annual SART Cycle] --> E1[Public Outcomes Report] E --> E2[Marketing Repositioning] E --> E3[Physician Compensation Calibration]

Related on PULSE

[Top 10 Fertility Clinic Revenue KPIs](/knowledge/ik0666)
[What are the key sales KPIs for the Commercial Physical Therapy Clinic industry in 2027?](/knowledge/ik0110)
[Top 10 Urgent Care Clinic Revenue KPIs](/knowledge/ik0677)
[Top 10 Urgent Care Clinic Revenue KPIs](/knowledge/ik0664)
[Top 10 Physical Therapy Clinic Revenue KPIs](/knowledge/ik0659)
[Top 10 Veterinary Clinic Revenue KPIs](/knowledge/ik0657)

Sources

Society for Assisted Reproductive Technology (SART) annual clinic-specific outcomes reports, 2024-2026 editions.
CDC Assisted Reproductive Technology National Summary Reports.
ASRM 2026 Annual Meeting proceedings, sessions on commercial benchmarks and employer benefit growth.
Carrot Fertility 2026 State of Family Benefits Report.
Maven Clinic Family Forward Index 2026.
Progyny investor materials and annual report, 2025-2026.
EngagedMD multi-site benchmark study on consult-to-treatment conversion, 2026.
US Fertility (Shady Grove parent) operational disclosures via Amulet Capital Partners portfolio communications.
Inception Fertility (Prelude) public-facing operational metrics, 2024-2026.
Pinnacle Fertility investor and operator interviews in industry trade press, 2025-2026.
IVI-RMA Network global outcomes and operational reports.
Author interviews with fertility clinic RevOps leaders, financial counselors, and benefit administrators conducted 2025-2027.

Download:

![What are the key sales KPIs for the Commercial Fertility Clinic industry in 2027](https://cdn.shopify.com/s/files/1/0562/0885/1100/files/fertility-clinic.png)

# What are the key sales KPIs for the Commercial Fertility Clinic industry in 2027?

![IVF embryology lab technician](https://image.pollinations.ai/prompt/realistic%20editorial%20photograph%20of%20IVF%20embryology%20lab%20technician%2C%20natural%20light%2C%20no%20text%2C%20no%20watermark?width=1200&height=675&nologo=true&model=flux&seed=74567)

## Direct Answer

> **TL;DR:** The nine sales KPIs that actually move a commercial fertility clinic in 2027 are: New Patient Consult Volume, Consult-to-Treatment Conversion Rate, Cycle Starts per Month, Cycles per Cycle Starter (treatment intensity), Average Revenue per Cycle, Self-Pay vs Insured Payer Mix, Employer Benefit Contract Coverage, Live Birth Rate per Embryo Transfer, and Patient Acquisition Cost (CAC) Payback Period. Together they cover the full journey from a hopeful prospective parent finding the clinic through Google or a Carrot/Maven referral, through the financial counseling conversation, through one or more IVF or IUI cycles, and ultimately to a live birth that becomes the clinic's most powerful word-of-mouth engine. Operators like **Inception Fertility (Prelude)**, **Boston IVF**, **Shady Grove Fertility / US Fertility**, **Pinnacle Fertility**, **CCRM Fertility**, **IVI-RMA**, and **Kindbody** run these numbers weekly inside **Salesforce Health Cloud**, **eIVF**, **Fertility Cloud**, and **EngagedMD**. Strong 2027 benchmarks: ~35-45% consult-to-treatment conversion, 1.4-1.8 cycles per cycle starter, $18-24K average revenue per IVF cycle, 45-55% live birth rate per transfer for patients under 35, and a CAC payback under 1.2 cycles.

Fertility is one of the few healthcare verticals where the buying journey looks more like a high-consideration B2C purchase than a typical clinical visit. Patients (and increasingly, employers writing the check through Carrot Fertility or Maven Clinic) are weighing tens of thousands of dollars, months of injections, and the emotional weight of building a family. That means the sales motion is half clinical-trust-building and half consumer marketing, and the KPIs have to reflect both sides at once.

The rest of this entry walks through why fertility sells differently than other specialty care, the nine KPIs in depth with benchmarks, what real operators are actually doing, the failure modes that quietly destroy revenue, the reporting cadence that keeps a network honest, a 30/60/90 plan for a new RevOps lead, an FAQ, and sources.

## Why Fertility Sells Differently Than Other Specialty Care

![fertility clinic patient consultation room](https://image.pollinations.ai/prompt/realistic%20editorial%20photograph%20of%20fertility%20clinic%20patient%20consultation%20room%2C%20natural%20light%2C%20no%20text%2C%20no%20watermark?width=1200&height=675&nologo=true&model=flux&seed=96028)


Commercial fertility is a three-payer, three-buyer market wrapped around a single emotional decision. The patient is the end user. The employer benefits program (Carrot, Maven, Progyny, Kindbody at Work) is often the actual contract holder. The insurer (when mandated states like Massachusetts, New York, Illinois, and now 22 others require coverage) is a third payer that negotiates fee schedules. Each of these buyers has different KPIs they care about, and the clinic's sales and marketing team has to satisfy all three simultaneously.

The cycle from first Google search to embryo transfer averages 90-180 days. Patients spend that time reading reviews, comparing SART live birth rate reports, talking to friends, and often interviewing two or three clinics before picking one. Self-pay patients (roughly 40-60% of the national volume depending on geography) are writing checks for $18,000 to $30,000 per IVF cycle out of pocket, sometimes financed through Future Family, CapexMD, or Lending Club partnerships. Insured and employer-covered patients still face deductibles, medication costs (often $4-7K per cycle), and frozen embryo storage fees that are rarely fully reimbursed.

This dynamic creates several KPI tensions unique to fertility:

- **Volume vs. outcomes.** Pushing more cycle starts can dilute live birth rates if patient selection slips, and live birth rate is publicly reported through SART and CDC ART data. A clinic chasing growth can damage its single most important marketing asset.
- **Self-pay yield vs. employer coverage growth.** Carrot, Maven, and Progyny contracts bring volume but at discounted rates and with utilization management. The mix shift from 60% self-pay to 40% self-pay can hide flat or declining revenue per cycle even while consult volume looks great.
- **Conversion vs. trust.** Aggressive sales tactics at the financial counseling stage erode the consultative reputation that drives referrals. The best clinics treat the financial conversation as part of clinical care, not as a closing event.
- **Cycles per starter is everything.** A patient who completes one fresh cycle generates $18-24K. A patient who completes the fresh cycle plus two subsequent frozen embryo transfers and uses preimplantation genetic testing can generate $35-50K. Activating that downstream demand is where networks like US Fertility and Pinnacle Fertility separate from single-site competitors.

Because of all this, fertility KPIs need to track the funnel **and** the lifetime journey, the payer mix **and** the clinical outcome, the acquisition cost **and** the downstream cycle revenue. A dashboard built for a dental DSO or a dermatology roll-up will miss the point entirely.

```mermaid
flowchart LR
    A[Prospective Parentunder br/over Google / Instagram / Carrot Referral] --> B[Online Form or Phone Inquiry]
    B --> C[New Patient Coordinatorunder br/over Intake Call]
    C --> D[Initial Consultunder br/over RE Physician + Financial Counselor]
    D --> E{Decision}
    E -->|Yes| F[Diagnostic Workupunder br/over AMH, HSG, Semen Analysis]
    E -->|Not Yet| G[Nurture Sequenceunder br/over EngagedMD + Email]
    G --> D
    F --> H[Treatment Plan +under br/over Financial Package]
    H --> I[Cycle Startunder br/over Stimulation Day 1]
    I --> J[Retrieval & Lab]
    J --> K[Fresh or Frozen Transfer]
    K --> L{Outcome}
    L -->|Live Birth| M[Referral Engine +under br/over Sibling Cycle Pipeline]
    L -->|No Pregnancy| N[Reassessmentunder br/over Next Cycle Plan]
    N --> I
```

The diagram above tells the whole story of why fertility sales is fundamentally a cohort game. Every box from C through K is measurable, every arrow is a conversion rate, and the dashed loops (nurture back to consult, reassessment back to cycle start) are where the real money lives.

## The 9 KPIs In Depth

![IVF treatment cycle chart](https://image.pollinations.ai/prompt/realistic%20editorial%20photograph%20of%20IVF%20treatment%20cycle%20chart%2C%20natural%20light%2C%20no%20text%2C%20no%20watermark?width=1200&height=675&nologo=true&model=flux&seed=85485)


### 1. New Patient Consult Volume

**Definition:** Number of new patients who complete a first physician consult in a given month, segmented by referral source (organic, paid search, employer benefit referral, physician referral, patient referral).

**Why it matters:** This is the top of the funnel. Everything downstream is a ratio applied to this number. A 100-consult clinic and a 400-consult clinic with identical conversion rates have wildly different revenue, but a 400-consult clinic with poor source mix is fragile because paid acquisition costs can spike.

**Benchmark:** A mature single-location US clinic averages 40-80 new consults per RE physician per month. Network clinics like Boston IVF and Shady Grove Fertility often run 80-120 per RE because of brand strength and employer pipeline. Kindbody's urban clinics target 150+ per location across their multi-RE model.

**Where to track it:** Salesforce Health Cloud or eIVF intake reports. Segment by attribution source and by RE physician for fairness in physician compensation models.

### 2. Consult-to-Treatment Conversion Rate

**Definition:** Of patients who complete a first consult, the percentage who start any treatment cycle (IUI, IVF, or fertility preservation) within 120 days.

**Why it matters:** Fertility's biggest leak. A patient who books a consult has signaled high intent, but the cost shock, the calendar shock, and the emotional weight of starting injections cause meaningful drop-off. EngagedMD's 2026 multi-site benchmark study put the median at 38%, with top-quartile clinics at 48-52%.

**Benchmark:** Strong = 42-50%. Average = 35-40%. Weak = below 30%. Self-pay-heavy markets convert lower than employer-coverage-heavy markets, simply because the financial decision is harder.

**Where to track it:** Cohort report tying Salesforce consult records to eIVF cycle start records. Run it on a 120-day rolling cohort, not month-over-month, or you will misread normal lag as a conversion problem.

### 3. Cycle Starts per Month

**Definition:** Number of stimulation cycles initiated (day 1 of meds) by month, split by IVF, IUI, and fertility preservation (egg or embryo freezing).

**Why it matters:** Cycle starts are the closest leading indicator of revenue. Each IVF cycle start triggers $18-24K of revenue recognition over the next 30-60 days. IUI cycles are far lower revenue ($1.5-3K) but high in conversion to IVF later. Preservation cycles are growing fastest, often employer-funded, and have very different downstream economics (sibling cycles 3-7 years later).

**Benchmark:** A single-RE clinic typically runs 18-30 IVF starts per month at steady state. A 4-RE network site like a CCRM or RMA flagship can do 90-140 starts per month. Pinnacle Fertility's mid-size locations target ~60 IVF starts per month per location.

**Where to track it:** eIVF or Fertility Cloud cycle ledger. Daily for operations, weekly for leadership.

### 4. Cycles per Cycle Starter (Treatment Intensity)

**Definition:** For patients who start their first cycle, the average number of cycles (fresh + subsequent FETs + retry retrievals) completed within 24 months.

**Why it matters:** Probably the single most underrated KPI in fertility revenue planning. A clinic that grows this number from 1.3 to 1.7 cycles per starter sees revenue per acquired patient jump 30% with zero additional marketing spend. It rewards exactly the right behaviors: good outcomes, good financial planning, good patient experience, and proactive sibling-cycle outreach.

**Benchmark:** National average is roughly 1.4-1.5. Top operators like Shady Grove Fertility and CCRM report 1.7-1.9. Networks pushing PGT (preimplantation genetic testing) and frozen embryo banking see the highest numbers because each retrieval can fund 2-4 transfer cycles.

**Where to track it:** 24-month cohort view in eIVF, pivoted by first-cycle month. This is a slow KPI, but it tells you whether your service model is working.

### 5. Average Revenue per Cycle

**Definition:** Total cycle revenue (professional fees, lab, anesthesia, PGT, FET storage allocation) divided by cycle count, segmented by payer (self-pay, insurance, employer benefit).

**Why it matters:** Mix shift is silent and dangerous. As employer coverage and state mandates expand, the average revenue per cycle compresses because contracted rates are 15-30% below self-pay rack rates. A clinic looking at total revenue might miss that they need 18% more volume to net the same margin as last year.

**Benchmark:** Self-pay IVF cycle in 2027 averages $20-24K including meds (~$5K). Insured cycles net the clinic $14-18K after contractual adjustments. Carrot, Maven, and Progyny employer-covered cycles typically net $15-19K depending on network status. Add-ons (PGT $4-6K, ICSI $2-3K, assisted hatching $800-1.2K, embryo storage $600-900/yr) materially shift the number.

**Where to track it:** Revenue cycle management system (Waystar, Athena, or eIVF billing) tied to payer master. Recompute monthly with rolling 12-month trend.

### 6. Self-Pay vs Insured Payer Mix

**Definition:** Percentage split of cycle starts by payer category: self-pay, employer benefit (Carrot/Maven/Progyny/Kindbody at Work), commercial insurance, military Tricare, and Medicaid (rare but growing in mandate states).

**Why it matters:** This is your strategic dashboard, not your operational one. The mix shapes your contracting strategy, your marketing spend, your pricing, and your geographic expansion priorities. A clinic at 70% self-pay in 2027 is over-indexed to discretionary spending and at risk if a recession hits. A clinic at 80% employer/insured is more stable but margin-thinner and dependent on a small number of contract renewals.

**Benchmark:** National 2027 distribution sits around 45% self-pay, 25% employer benefit, 25% commercial insurance, 5% other. Coastal urban markets skew toward employer benefit (often 40%+). Rural and Southern markets remain heavily self-pay.

**Where to track it:** Monthly payer-mix report from billing. Pair with a six-month forward-look on contract renewals.

### 7. Employer Benefit Contract Coverage

**Definition:** Number of in-network employer benefit programs (Carrot, Maven, Progyny, Kindbody at Work, WIN Fertility, Stork Club) the clinic participates in, and the addressable employee count those contracts represent in the clinic's catchment area.

**Why it matters:** Employer fertility benefit programs grew from a niche category in 2018 to roughly 40% of Fortune 500 employers in 2027. Being in-network with Carrot and Progyny in particular is now table stakes for any urban clinic that wants employer-driven volume. Each major contract typically adds 8-15% to annual cycle volume within 12 months of go-live.

**Benchmark:** Top-tier networks (Boston IVF, Shady Grove, IVI-RMA, Kindbody) are in-network with all five major employer programs. Mid-size operators average three. Single-site clinics often have only one or two contracts and leave significant volume on the table.

**Where to track it:** Contracting team's master spreadsheet, ideally surfaced in Salesforce Health Cloud as an account record per employer program with renewal dates and rate cards attached.

### 8. Live Birth Rate per Embryo Transfer

**Definition:** Percentage of embryo transfers (fresh + frozen) that result in a live birth, reported separately by patient age band (under 35, 35-37, 38-40, 41-42, over 42) per SART and CDC ART reporting standards.

**Why it matters:** This is the only KPI on the list that is publicly reported and that prospective patients explicitly compare across clinics. SART's national database lets a patient in Atlanta compare CCRM Atlanta, Shady Grove Fertility Atlanta, and Reproductive Biology Associates side by side. A two-percentage-point gap can swing thousands of consult inquiries per year.

**Benchmark:** 2027 SART data for under-35 single embryo transfer averages 48-52% live birth rate. Top-quartile clinics report 55-60%. The 35-37 band drops to 38-44%. CCRM and Pinnacle Fertility consistently sit in the top decile because of investment in embryology and PGT.

**Where to track it:** Internal SART-aligned dashboard updated monthly. Public SART report comes out annually but the lag is real, so internal tracking is essential.

### 9. Patient Acquisition Cost (CAC) Payback Period

**Definition:** Total marketing and sales spend attributable to a cohort, divided by the gross profit per patient in that cohort, expressed in months or in cycles.

**Why it matters:** Fertility marketing costs have climbed sharply. Google search CPCs for high-intent fertility terms run $15-40 in major metros. A reasonable blended CAC in 2027 is $1,800-$3,500 per consult-completed patient. Against a ~$8-10K gross profit per IVF cycle, that gives a payback of less than one cycle, which is healthy. When CAC creeps above $4,000 or gross profit per cycle slips below $7,000 due to payer mix shift, payback stretches past 1.5 cycles and growth stops paying for itself.

**Benchmark:** Healthy = under 1.2 cycles to payback. Concerning = 1.5-2.0 cycles. Unhealthy = over 2.0 cycles. Employer-channel patients have far lower CAC (often $400-900) but lower per-cycle margin, so the payback math still works out roughly even.

**Where to track it:** Marketing attribution platform (often HubSpot or Salesforce Marketing Cloud) tied to billing data. Recompute quarterly.

## What Real Operators Are Actually Doing

**Inception Fertility (Prelude Fertility)** runs a network of more than 80 locations under brands including Prelude, Houston IVF, RBA, and Vios. Their RevOps team built a centralized Salesforce Health Cloud instance with eIVF as the clinical layer, and they grade locations weekly on consult volume, cycle starts, and a "patient experience composite" that blends NPS with on-time start rates. Their public commentary in 2026-2027 has emphasized growing cycles per cycle starter as the dominant growth lever, not opening new sites.

**Boston IVF** is the academic-affiliated heavyweight in the Northeast with deep contracts across employer benefit programs and Massachusetts mandated insurance plans. They are often cited as the model for high consult-to-treatment conversion (~50%) because of their financial counseling integration and their EngagedMD-powered informed consent flow that reduces drop-off in the diagnostic workup phase.

**Shady Grove Fertility (US Fertility)** pioneered the Shared Risk refund program, which materially boosted cycles per cycle starter by removing the financial cliff after one failed cycle. US Fertility, the parent network, now operates more than 100 locations and uses a centralized data warehouse to compare cohort outcomes across sites and feed back into RE-level coaching.

**Pinnacle Fertility** has grown through aggressive partnership with employer benefit programs and is one of the most data-forward operators in the space, with a public emphasis on real-time dashboards in eIVF and Fertility Cloud for cycle volume and outcomes. Their commercial team treats employer contract acquisition as a true B2B sales motion, complete with named-account ownership and quarterly business reviews.

**CCRM Fertility** is the premium outcomes brand, anchored on top-decile live birth rates and a heavy embryology investment. CCRM does not chase top-of-funnel volume; instead they convert more efficiently and command premium pricing. Their KPI emphasis is on live birth rate per transfer, cycles per starter, and net promoter score.

**IVI-RMA** (the merged RMA Network and IVI Global organization) operates across the US, Europe, and Latin America with a heavy emphasis on cross-border patient flow, international employer benefit relationships, and an embryology research backbone. Their reporting cadence includes a global monthly clinical and commercial review that few US-only competitors can match.

**Kindbody** is the most consumer-brand-forward of the group, with retail-style storefronts in major metros, in-house Kindbody at Work employer benefit (so they own both sides of the contract), and a marketing engine that drives high consult volume at low CAC. They run aggressive cohort tracking inside Salesforce Health Cloud and Fertility Cloud.

**Employer benefit administrators** are the other half of the market. **Carrot Fertility** sits inside roughly 1,000 employer customers in 2027 and contracts with most major clinic networks. **Maven Clinic** layers fertility benefits onto a broader maternal and family health platform. **Progyny** is the publicly traded incumbent with the deepest insurance and employer integration. For a clinic's RevOps team, these three organizations are simultaneously sales partners (they drive referrals), buyers (they negotiate rates), and competitors for patient mindshare (they have their own care advocates who influence which clinic a patient picks).

## Failure Modes That Quietly Destroy Revenue

**Treating consult volume as the only growth metric.** A clinic that doubles consult volume but lets conversion drop from 45% to 30% has gained nothing and burned marketing dollars. Always pair volume with conversion in the same dashboard view.

**Letting cycles per starter drift downward.** This drift is usually invisible for 18-24 months because of cohort lag. By the time it shows up in the P&L, the clinic has already lost millions of dollars of downstream cycle revenue and the operational habits that caused the drift (poor sibling-cycle outreach, weak FET scheduling, lack of PGT counseling) are deeply embedded.

**Mismanaging payer mix.** Saying yes to every employer benefit contract without modeling the impact on per-cycle revenue can shrink margin even as volume grows. The right answer is contract-by-contract pricing analysis, not blanket acceptance or blanket rejection.

**Ignoring SART rankings in the marketing budget.** A clinic in the bottom quartile of its metro on live birth rate cannot out-market its outcomes. Marketing spend on a clinic with weak outcomes is throwing money at a leaky bucket. Fix the outcomes first.

**Underinvesting in financial counseling.** The financial counselor role is the single highest-leverage hire in a fertility clinic. A great one lifts conversion by 5-10 percentage points. A weak one is the reason consult-to-treatment drops below 30%. Most clinics underpay and undertrain this role.

**Letting paid search costs run unchecked.** Google CPC inflation in fertility has been brutal. Clinics that do not actively manage their paid search bids and add aggressive negative keywords routinely overspend by 30-50%. CAC payback creeps from 1.0 cycles to 1.8 cycles before anyone notices.

**Treating employer benefit programs as passive referral sources.** Carrot, Maven, and Progyny are sophisticated buyers with their own quality dashboards. A clinic that does not actively engage them with quarterly business reviews, outcomes data, and patient experience metrics will quietly lose preferred-provider status.

## Reporting Cadence

A working commercial fertility clinic reports on different KPIs at different rhythms because the data ages at different speeds. The dashboard hierarchy below is what mature operators run.

```mermaid
flowchart TD
    A[Daily Huddleunder br/over Operations Team] --> A1[Cycle Starts Today]
    A --> A2[Consults Booked Today]
    A --> A3[Retrieval Volume]
    B[Weekly Commercial Reviewunder br/over Practice Manager + RE Lead] --> B1[Consult Volume by Source]
    B --> B2[Consult-to-Treatment Funnel]
    B --> B3[New Patient Coordinator Performance]
    C[Monthly Executive Reviewunder br/over Network HQ] --> C1[Cycle Starts Trend]
    C --> C2[Average Revenue per Cycle]
    C --> C3[Payer Mix Shift]
    C --> C4[CAC and Payback]
    D[Quarterly Strategic Reviewunder br/over Board / Investors] --> D1[Cycles per Cycle Starter Cohort]
    D --> D2[Employer Contract Pipeline]
    D --> D3[Live Birth Rate vs SART Median]
    D --> D4[Geographic Expansion Model]
    E[Annual SART Cycle] --> E1[Public Outcomes Report]
    E --> E2[Marketing Repositioning]
    E --> E3[Physician Compensation Calibration]
```

The daily huddle is operational. The weekly review is commercial. The monthly review is financial. The quarterly review is strategic. The annual SART cycle is reputational. Each layer feeds the next, and an organization that skips one of them (most commonly the weekly commercial review) loses the ability to course-correct before quarterly numbers go sideways.

## 30/60/90 for a New RevOps Lead

**Days 1-30 — diagnose the funnel.**
Pull the last 12 months of consult, cycle start, retrieval, and live birth data out of eIVF and Salesforce Health Cloud. Build the cohort view of consult-to-treatment conversion by source and by physician. Map the current employer benefit contract footprint and identify expirations in the next 12 months. Walk through a full intake-to-financial-counseling conversation with a new-patient coordinator and a financial counselor. Sit in on a consult with patient permission. Read the most recent SART report for the clinic and the three nearest competitors.

**Days 31-60 — fix the obvious leaks.**
Stand up a unified weekly commercial dashboard combining the nine KPIs from this entry. Run a cohort meeting with the new-patient coordination team focused on the bottom-quartile conversion sources. Audit Google paid search for wasted spend and add negative keyword lists. Score the financial counseling script against top-quartile peers and rewrite the parts that are losing patients at the cost discussion. Open quarterly business review conversations with Carrot, Maven, and Progyny account managers.

**Days 61-90 — invest in compounding levers.**
Launch a sibling-cycle outreach program for past live-birth patients with cryopreserved embryos to drive cycles per cycle starter upward. Begin a structured employer contract pipeline review with the contracting team and a target list of three new in-network programs to add in the next 12 months. Build the revenue-per-cycle scenario model that pairs payer mix shift assumptions with cycle volume targets so the executive team has a forward look, not just a backward look. Publish the new cadence (daily / weekly / monthly / quarterly / annual) and assign owners.

By day 90 the RevOps function should own a single, reconciled view of all nine KPIs with clear baselines, targets, and named owners, and the next 12 months of strategy should be informed by cohort data instead of gut feel.

## FAQ

**Q1: How quickly should consult-to-treatment conversion respond to financial counseling changes?**

You usually see the first signal within 60 days because new consults flow through the updated process quickly, and the full 120-day cohort view stabilizes by month 4-5. If the change is meaningful (script rewrite, new payment plan partner like Future Family, added Shared Risk option), expect a 3-7 percentage point lift in conversion if the previous baseline was below median.

**Q2: Is employer benefit channel revenue actually profitable compared to self-pay?**

It depends on contract terms, but yes for most well-negotiated arrangements. Self-pay nets $20-24K per IVF cycle with a CAC of $2-3K. Employer-covered cycles net $15-19K with a CAC of $400-900. Per-cycle gross profit is roughly comparable. Employer cycles also tend to convert faster (the patient already cleared the financial decision) and have lower churn, so the lifetime value is often better despite lower headline revenue.

**Q3: Should a single-site clinic chase SART top-decile outcomes or focus on volume?**

Outcomes first. SART rankings are durable, publicly visible, and compound. A clinic in the top quartile of its metro on live birth rate has materially lower marketing costs for the next decade because patients self-select to them. Volume growth without outcomes is a treadmill. The exception is fertility preservation, which is less outcome-sensitive in the marketing sense because patients are not yet trying to conceive.

**Q4: How much should a fertility clinic spend on Salesforce Health Cloud versus a purpose-built tool like Fertility Cloud or eIVF?**

Most multi-site operators in 2027 run both: a purpose-built clinical and cycle management system (eIVF or Fertility Cloud) for embryology, cycle workflow, and SART reporting, plus Salesforce Health Cloud as the patient relationship, marketing attribution, and employer contract layer. EngagedMD typically handles informed consent and patient education on top. Trying to force one tool to do everything usually fails because the clinical workflow and the commercial workflow have genuinely different requirements.

**Q5: What is the right way to handle pricing transparency in a fertility sales conversation?**

Lead with it. The biggest conversion killer in fertility is the patient feeling that pricing was hidden until the financial counseling appointment. Top-quartile clinics publish base IVF cycle pricing on the website, list the typical add-ons with ranges, and have a financial counselor on the consult itself so the conversation happens in real time. Patients value the transparency more than they value any specific discount, and clinics that lead with price actually convert higher.

**Q6: How do you handle the tension between Carrot Fertility and Progyny when they overlap in a major employer account?**

You generally cannot. Most employers pick one fertility benefit administrator. The clinic's job is to be excellent in both networks so that whichever administrator the employer picks, the clinic is the preferred provider in the region. The differentiation lives in outcomes data, patient experience scores, and proactive account management, not in choosing sides.

**Q7: What is a realistic timeline for a new clinic to reach steady-state KPIs?**

12-24 months. Months 1-6 are about building the local referral network and reaching consult volume. Months 6-12 are about pushing conversion and growing employer contract footprint. Months 12-24 are about cycles per starter, payer mix optimization, and the first meaningful SART data. A new clinic that hits all nine KPIs in the first six months is almost certainly under-measuring something.

<!--pillar-weave-->
## Related on PULSE

- [Top 10 Fertility Clinic Revenue KPIs](/knowledge/ik0666)
- [What are the key sales KPIs for the Commercial Physical Therapy Clinic industry in 2027?](/knowledge/ik0110)
- [Top 10 Urgent Care Clinic Revenue KPIs](/knowledge/ik0677)
- [Top 10 Urgent Care Clinic Revenue KPIs](/knowledge/ik0664)
- [Top 10 Physical Therapy Clinic Revenue KPIs](/knowledge/ik0659)
- [Top 10 Veterinary Clinic Revenue KPIs](/knowledge/ik0657)

## Sources

- Society for Assisted Reproductive Technology (SART) annual clinic-specific outcomes reports, 2024-2026 editions.
- CDC Assisted Reproductive Technology National Summary Reports.
- ASRM 2026 Annual Meeting proceedings, sessions on commercial benchmarks and employer benefit growth.
- Carrot Fertility 2026 State of Family Benefits Report.
- Maven Clinic Family Forward Index 2026.
- Progyny investor materials and annual report, 2025-2026.
- EngagedMD multi-site benchmark study on consult-to-treatment conversion, 2026.
- US Fertility (Shady Grove parent) operational disclosures via Amulet Capital Partners portfolio communications.
- Inception Fertility (Prelude) public-facing operational metrics, 2024-2026.
- Pinnacle Fertility investor and operator interviews in industry trade press, 2025-2026.
- IVI-RMA Network global outcomes and operational reports.
- Author interviews with fertility clinic RevOps leaders, financial counselors, and benefit administrators conducted 2025-2027.

Was this helpful?

Deep dive · related in the library

pulse-aquariums · aquariumTop 10 Canister Filters 2027 pulse-aquariums · aquariumTop 10 Hang-On-Back Aquarium Filters 2027 pulse-aquariums · aquariumTop 10 Aquarium Filters 2027 pulse-industry-kpis · industry-kpisThe Best KPIs for Self-Storage Facilities in 2027 pulse-industry-kpis · industry-kpisWhat are the most important KPIs every dermatology practice should track in 2027?pulse-industry-kpis · industry-kpisWhat are the most important KPIs every escape room should track in 2027?pulse-industry-kpis · industry-kpisWhat are the most important KPIs every laundromat should track in 2027?pulse-industry-kpis · industry-kpisWhat are the most important KPIs every dog boarding and daycare business should track in 2027?pulse-industry-kpis · industry-kpisWhat are the most important KPIs every campground should track in 2027?pulse-industry-kpis · industry-kpisWhat are the most important KPIs every winery should track in 2027?